pharmaphorum

JANUARY 16, 2023

Rapid growth is forecasted from 2023 onwards: some industry observers predict that the global POC and rapid Dx market projected to reach $75bn by 2027, up from $45bn in 2022, at a CAGR of 10.7%. Innovation will power the market.

Pharmaceutical Companies 98

Pharmaceutical Companies Pharmaceutical Companies Compounding Vaccines 98

European Pharmaceutical Review

OCTOBER 12, 2023

Sustainability in pharmaceutical manufacturing AstraZeneca – biomethane supply AstraZeneca will establish the first industrial-scale supply of biomethane” In mid-September, a 15-year partnership between AstraZeneca and Future Biogas was agreed. Interestingly, the facility will be sited at a university campus, Carlsen revealed.

Pharmaceutical Manufacturing 104

Pharmaceutical Manufacturing Vaccines Dosage Pharmaceutical Companies 104

pharmaphorum

JANUARY 27, 2023

On the report’s findings, Steve Bates OBE, CEO of the BIA, said: “UK-based life sciences companies are worldleading in developing life changing medical innovation. Bates continued: “We expected a fall in investment following two bumper years, but it should still be considered a warning.

Compounding 52

Compounding Pharmaceutical Companies Pharmaceutical Companies 52

Pharmaceutical Technology

NOVEMBER 4, 2022

of gross domestic product (GDP) in R&D by 2027. In support of this, Turner says that the budget for Innovate UK , the funding agency that provides grants to life science companies, was increased by 30% over the last few years. UK’s competitive potential.

Documentation 93

Documentation Pharmaceutical Companies Pharmaceutical Companies 93

European Pharmaceutical Review

MARCH 7, 2024

billion between 2022 to 2027. Lastly, there is growing prominence and interest in radioligand therapeutics within major pharmaceutical companies, who are increasingly investing in this field, evident through recent acquisitions of Point Biopharma and RayzeBio.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies Immunity Immunization 52

Viseven

JUNE 12, 2023

from 2022 to 2027. Specifically, she engaged with several important stakeholders and received valuable information about future sales and marketing strategies, decision-making vision, and innovation trends among Chinese pharmaceutical companies. This role is significant because the pharma market in APAC is increasing.

Communication 52

Communication Pharmaceutical Companies Pharmaceutical Companies Packaging 52

Pharmaceutical Technology

JANUARY 10, 2023

There are multiple drugs in the pipeline, predominantly me-too and biosimilar therapies, with a significant number developed in the emerging markets of India and China by domestic pharmaceutical companies for their own rapidly growing markets.

Biosimilars 52

Biosimilars Labelling Diabetes Compounding 52

pharmaphorum

JANUARY 6, 2022

The EU4Health 2021-2027 budget earmarks €5.3bn to, among other actions, strengthen health data and digital transformation across the EU. Sarah Rickwood has 30 years’ experience as a consultant to the pharmaceutical industry, having worked in Accenture’s pharmaceutical strategy practice prior to joining IQVIA.

Vaccines 111

Vaccines Pharmaceutical Companies Pharmaceutical Companies 111

Pharmaceutical Technology

APRIL 24, 2023

As a result, some pharmaceutical companies are turning to third parties. GlobalData forecasts Biologics to significantly overtake sales of small molecules by $120 billion by 2027. Moreover, skilled manpower is required to run these facilities.

Vaccines 52

Vaccines Compounding Communication Immunization 52

Pharmaceutical Technology

FEBRUARY 6, 2023

A Pliant spokesperson said, “This successful transaction, along with existing cash, cash equivalents, loan agreement and short-term investments, provides for operations to be funded to mid-2027, a year past the expected IPF Phase 2b clinical trial readout.” The company said a Phase IIb trial initiation should be expected in mid-2023.

Communication 59

Communication Pharmaceutical Companies Pharmaceutical Companies 59